Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Some three years after regulators in the USA rejected flibanserin, Sprout Pharmaceuticals has resubmitted the female sexual dysfunction drug acquired from Boehringer Ingelheim to the Food and Drug Administration. In June 2010, the agency’s Reproductive Health Drugs Advisory Committee voted 10-1 that flibanserin is not effective in increasing female libido and unanimously ruled that its potential side effects, such as loss of consciousness and depression, were not acceptable. Boehringer discontinued development of the compound a few months later but then sold it to Sprout in 2011.
Help employers find you! Check out all the jobs and post your resume.
